<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262301</url>
  </required_header>
  <id_info>
    <org_study_id>C1 1304-01</org_study_id>
    <nct_id>NCT00262301</nct_id>
  </id_info>
  <brief_title>Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary angioedema (&quot;HAE&quot;) is a genetic disorder characterized by sudden recurrent attacks
      of local swelling (angioedema). These attacks are often painful and disabling, and, in some
      cases, life-threatening. &quot;HAE&quot; is caused by mutations in the &quot;C1INH&quot; gene that leads to a
      decrease in the blood level of functional &quot;C1INH&quot;. This multi-center study was designed to
      assess the safety and tolerability, efficacy and pharmacodynamics/ pharmacokinetics of
      recombinant human C1 inhibitor (&quot;rhC1INH&quot;) in the treatment of acute hereditary angioedema
      attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospectively planned interim analysis will be performed on the double-blind data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Beginning of Relief of Symptoms</measure>
    <time_frame>up to 48 hours after study drug administration</time_frame>
    <description>The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale (&quot;VAS&quot;) ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first &quot;VAS&quot; score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Minimal Symptoms</measure>
    <time_frame>up to 48 hours after study drug administration</time_frame>
    <description>the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale (&quot;VAS&quot;) score. Symptoms were said to be minimal when the &quot;VAS&quot; score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>Angioneurotic Edema</condition>
  <condition>Genetic Disorders</condition>
  <arm_group>
    <arm_group_label>100 IU/kg &quot;rhC1INH&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 IU/kg recombinant human C1 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human C1 inhibitor</intervention_name>
    <description>IV</description>
    <arm_group_label>100 IU/kg &quot;rhC1INH&quot;</arm_group_label>
    <other_name>&quot;rhC1INH&quot;</other_name>
    <other_name>Ruconest</other_name>
    <other_name>conestat alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>saline</other_name>
    <other_name>physiological salt solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clear clinical and laboratory diagnosis of HAE

          -  Baseline plasma level of functional C1INH of less than 50% of normal

          -  Evidence for exacerbation or development of a severe abdominal, oro-facial/
             pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack

        Exclusion Criteria:

          -  Acquired angioedema

          -  Pregnancy or breastfeeding

          -  Participation in another clinical study within prior 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Nuijens, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharming Group N.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For information on sites, please contact Pharming Medical Affairs Deparment</name>
      <address>
        <city>Leiden</city>
        <zip>2300 AL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department</name>
      <address>
        <city>Tirgu Mures</city>
        <zip>541103</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <results_reference>
    <citation>Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14. doi: 10.1016/j.jaci.2010.07.021.</citation>
    <PMID>20920772</PMID>
  </results_reference>
  <results_reference>
    <citation>Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M, Triggiani M, Montinaro V, Cillari E, Realdi G, Cancian M, Visscher S, Zanichelli A, Relan A, Cicardi M. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy. 2012 Jun;42(6):929-35. doi: 10.1111/j.1365-2222.2012.03984.x.</citation>
    <PMID>22909164</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>July 27, 2012</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During the double-blind phase of the study, patients were randomized once to receive 100 IU/kg &quot;rhC1INH&quot; or Saline in a ratio of 1:1. After conclusion of the double-blind phase, patients with subsequent eligible attacks could be treated with open-label 1 vial (2100 IU) of &quot;rhC1INH&quot;.</recruitment_details>
      <pre_assignment_details>Patients could be enrolled into the open-label phase of the study after conclusion of the double-blind phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100 IU/kg &quot;rhC1INH&quot;</title>
          <description>Includes all subjects randomized and who received 100 IU/kg recombinant human C1 inhibitor in the double-blind phase.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Includes all subjects randomized and who received Saline solution in the double-blind phase.</description>
        </group>
        <group group_id="P3">
          <title>1 Vial (2100 IU) &quot;rhC1INH&quot;</title>
          <description>Includes all subjects who received, 1 vial (2100 IU) open-label &quot;rhC1INH&quot; in the open-label extension phase. Patients received 1 vial initially and could receive an additional 1-2 vials within 4 hours at the investigator's discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>worsening of &quot;HAE&quot; symptoms</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="57">14/57 patients crossed over from the double-blind phase (7/14 were treated with 100 U/kg &quot;rhC1INH&quot;)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>100 IU/kg &quot;rhC1INH&quot;</title>
          <description>Includes all subjects randomized who received 100 IU/kg recombinant human C1 inhibitor in the double-blind phase.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Includes all subjects randomized and who received Saline solution in the double-blind phase.</description>
        </group>
        <group group_id="B3">
          <title>1 Vial (2100 IU) &quot;rhC1INH&quot;</title>
          <description>Includes all subjects who received 1 vial (2100 IU) open-label &quot;rhC1INH&quot; in the open-label extension phase.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Beginning of Relief of Symptoms</title>
        <description>The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale (&quot;VAS&quot;) ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first &quot;VAS&quot; score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.</description>
        <time_frame>up to 48 hours after study drug administration</time_frame>
        <population>The full analysis set (&quot;FAS&quot; or &quot;mITT&quot;) was defined as the set of patients who provided Informed Consent, were randomized and took at least one dose of the study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>100 IU/kg &quot;rhC1INH&quot;</title>
            <description>Includes all subjects randomized who received 100 IU/kg recombinant human C1 inhibitor in the double-blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Includes all subjects randomized and who received Saline solution in the double-blind phase.</description>
          </group>
          <group group_id="O3">
            <title>1 Vial (2100 IU) &quot;rhC1INH&quot;</title>
            <description>Includes all subjects who received 1 vial (2100 IU) open-label &quot;rhC1INH&quot; in the open-label extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Beginning of Relief of Symptoms</title>
          <description>The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale (&quot;VAS&quot;) ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first &quot;VAS&quot; score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.</description>
          <population>The full analysis set (&quot;FAS&quot; or &quot;mITT&quot;) was defined as the set of patients who provided Informed Consent, were randomized and took at least one dose of the study drug administration.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="15" upper_limit="1470"/>
                    <measurement group_id="O2" value="508" lower_limit="15" upper_limit="2880"/>
                    <measurement group_id="O3" value="61" lower_limit="15" upper_limit="1455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Minimal Symptoms</title>
        <description>the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale (&quot;VAS&quot;) score. Symptoms were said to be minimal when the &quot;VAS&quot; score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.</description>
        <time_frame>up to 48 hours after study drug administration</time_frame>
        <population>The full analysis set (&quot;FAS&quot; or &quot;mITT&quot;) was defined as the set of patients who provided Informed Consent, were randomized and took at least one dose of study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>100 IU/kg &quot;rhC1INH&quot;</title>
            <description>Includes all subjects randomized who received 100 IU/kg recombinant human C1 inhibitor in the double-blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Includes all subjects randomized and who received Saline solution in the double-blind phase.</description>
          </group>
          <group group_id="O3">
            <title>1 Vial (2100 IU) &quot;rhC1INH&quot;</title>
            <description>Includes all subjects who received 1 vial (2100 IU) open-label &quot;rhC1INH&quot; in the open-label extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Minimal Symptoms</title>
          <description>the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale (&quot;VAS&quot;) score. Symptoms were said to be minimal when the &quot;VAS&quot; score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.</description>
          <population>The full analysis set (&quot;FAS&quot; or &quot;mITT&quot;) was defined as the set of patients who provided Informed Consent, were randomized and took at least one dose of study drug administration.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480" lower_limit="15" upper_limit="2400"/>
                    <measurement group_id="O2" value="1440" lower_limit="31" upper_limit="2885"/>
                    <measurement group_id="O3" value="241" lower_limit="15" upper_limit="4333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-Emergent-Adverse-Events (&quot;TEAEs&quot;) were defined as events with start from onset of study drug administration. Serious Adverse events and Adverse events for each arm with onset dates within 7 days of study drug administration have been listed.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>100 IU/kg &quot;rhC1INH&quot;</title>
          <description>Includes all subjects randomized who received 100 IU/kg recombinant human C1 inhibitor in the double-blind phase.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Includes all subjects randomized and who received Saline solution in the double-blind phase.</description>
        </group>
        <group group_id="E3">
          <title>1 Vial (2100 IU) &quot;rhC1INH&quot;</title>
          <description>Includes all subjects who received 1 vial (2100 IU) open-label &quot;rhC1INH&quot; in the open-label extension phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostate examination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menstrual disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>scrotal swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to its submission or disclosure. The sponsor may request to delete information identified by sponsor as confidential information prior to submitting such manuscript and/or abstract for publication. For a multi-center study, the investigator must wait (i) at least 24 months after the study is completed at all sites or (ii) until after the multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Department</name_or_title>
      <organization>Pharming Technologies BV</organization>
      <phone>+31715247400</phone>
      <email>medicalinfo@pharming.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

